SEC Info - Mednax, Inc. - ‘10-Q’ for 3/31/20

Mednax, Inc. – ‘10-Q’ for 3/31/20

Mednax, Inc. – ‘10-Q’ for 3/31/20

On: Thursday, 5/7/20, at 4:26pm ET · For: 3/31/20 · Accession #: 1193125-20-136311 · File #: 1-12111

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

‘10-Q’ — Quarterly Report
Document Table of Contents

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

4 Subsequent Filings that Reference this Filing

On: Thursday, 5/7/20, at 4:26pm ET · For: 3/31/20 · Accession #: 1193125-20-136311 · File #: 1-12111

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘10-Q’ — Quarterly ReportDocument Table of Contents

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

4 Subsequent Filings that Reference this Filing

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

‘10-Q’ — Quarterly Report
Document Table of Contents

SEC Info℠

Home

Help

Please Sign In

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/07/20  Mednax, Inc.                      10-Q        3/31/20   57:5.4M                                   Donnelley … Solutions/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    557K 
 2: EX-10.1     Material Contract                                   HTML    697K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
47: R1          Cover Page                                          HTML     72K 
31: R2          Consolidated Balance Sheets (Unaudited)             HTML    116K 
14: R3          Consolidated Balance Sheets (Unaudited)             HTML     35K 
                (Parenthetical)                                                  
38: R4          Consolidated Statements of Income                   HTML    122K 
46: R5          Consolidated Statements of Equity                   HTML     71K 
30: R6          Consolidated Statements of Cash Flows               HTML    141K 
13: R7          Basis of Presentation and New Accounting            HTML     29K 
                Pronouncements                                                   
39: R8          Coronavirus Pandemic ("Covid-19")                   HTML     34K 
45: R9          Cash Equivalents and Investments                    HTML     37K 
27: R10         Fair Value Measurements                             HTML     61K 
19: R11         Accounts Receivable and Net Revenue                 HTML     64K 
33: R12         Discontinued Operations                             HTML     25K 
54: R13         Accounts Payable and Accrued Expenses               HTML     41K 
26: R14         Common and Common Equivalent Shares                 HTML     39K 
18: R15         Stock Incentive Plans and Stock Purchase Plans      HTML     27K 
32: R16         Common Stock Repurchase Programs                    HTML     24K 
53: R17         Commitments and Contingencies                       HTML     26K 
25: R18         Subsequent Event                                    HTML     46K 
20: R19         Basis of Presentation and New Accounting            HTML     22K 
                Pronouncements (Policies)                                        
41: R20         Cash Equivalents and Investments (Tables)           HTML     34K 
50: R21         Fair Value Measurements (Tables)                    HTML     58K 
29: R22         Accounts Receivable and Net Revenue (Tables)        HTML     67K 
12: R23         Accounts Payable and Accrued Expenses (Tables)      HTML     39K 
40: R24         Common and Common Equivalent Shares (Tables)        HTML     37K 
49: R25         Subsequent Event (Table)                            HTML     50K 
28: R26         Basis of Presentation and New Accounting            HTML     24K 
                Pronouncements - Additional Information (Detail)                 
11: R27         Coronavirus Pandemic ("COVID-19") - Additional      HTML     55K 
                Information (Detail)                                             
42: R28         Cash Equivalents and Investments - Additional       HTML     22K 
                Information (Detail)                                             
48: R29         Cash Equivalents and Investments - Schedule of      HTML     29K 
                Investments (Detail)                                             
55: R30         Fair Value Measurements - Schedule of fair value    HTML     33K 
                on a recurring basis (Details)                                   
36: R31         Fair Value Measurements - Schedule of financial     HTML     29K 
                instruments that are not carried at fair value                   
                (Details)                                                        
16: R32         Accounts Receivable and Net Revenue - Schedule of   HTML     27K 
                Accounts Receivable, Net (Detail)                                
22: R33         Accounts Receivable and Net Revenue - Schedule of   HTML     27K 
                Net Revenue (Detail)                                             
56: R34         Accounts Receivable and Net Revenue - Schedule of   HTML     30K 
                Net Patient Service Revenue by Type of Payor                     
                (Detail)                                                         
37: R35         Discontinued Operations - Additional Information    HTML     31K 
                (Detail)                                                         
17: R36         Accounts Payable and Accrued Expenses - Schedule    HTML     40K 
                of Accounts Payable and Accrued Expenses (Detail)                
23: R37         Accounts Payable and Accrued Expenses - Additional  HTML     18K 
                Information (Detail)                                             
57: R38         Common and Common Equivalent Shares - Schedule of   HTML     31K 
                Calculation of Shares Used in Basic and Diluted                  
                Net Income Per Share (Detail)                                    
35: R39         Stock Incentive Plans and Stock Purchase Plans -    HTML     59K 
                Additional Information (Detail)                                  
51: R40         Common Stock Repurchase Programs - Additional       HTML     28K 
                Information (Detail)                                             
43: R41         Subsequent Event - Additional information (Detail)  HTML     34K 
15: R42         Subsequent Event - Summary of Major Classes of      HTML     63K 
                Assets and Liabilities (Detail)                                  
21: XML         IDEA XML File -- Filing Summary                      XML     97K 
24: XML         XBRL Instance -- d888266d10q_htm                     XML    749K 
52: EXCEL       IDEA Workbook of Financial Reports                  XLSX     45K 
 7: EX-101.CAL  XBRL Calculations -- md-20200331_cal                 XML    141K 
 8: EX-101.DEF  XBRL Definitions -- md-20200331_def                  XML    318K 
 9: EX-101.LAB  XBRL Labels -- md-20200331_lab                       XML    790K 
10: EX-101.PRE  XBRL Presentations -- md-20200331_pre                XML    560K 
 6: EX-101.SCH  XBRL Schema -- md-20200331                           XSD    115K 
44: JSON        XBRL Instance as JSON Data -- MetaLinks              243±   353K 
34: ZIP         XBRL Zipped Folder -- 0001193125-20-136311-xbrl      Zip    276K

Page	(sequential)	(alphabetic)	↑Top
		Alternative Formats (Word, et al.) Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 (Unaudited) Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019 (Unaudited) Consolidated Statements of Equity for the Three Months Ended March 31, 2020 and 2019 (Unaudited) Consolidated Statements of Income for the Three Months Ended March 31, 2020 and 2019 (Unaudited) Controls and Procedures Exhibits Legal Proceedings Management's Discussion and Analysis of Financial Condition and Results of Operations Notes to Consolidated Financial Statements (Unaudited) Quantitative and Qualitative Disclosures About Market Risk Risk Factors Signatures Table of Contents Unregistered Sales of Equity Securities and Use of Proceeds
1	1st Page – Filing Submission
"	Table of Contents
"	Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 (Unaudited)
"	Consolidated Statements of Income for the Three Months Ended March 31, 2020 and 2019 (Unaudited)
"	Consolidated Statements of Equity for the Three Months Ended March 31, 2020 and 2019 (Unaudited)
"	Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019 (Unaudited)
"	Notes to Consolidated Financial Statements (Unaudited)
"	Management's Discussion and Analysis of Financial Condition and Results of Operations
"	Quantitative and Qualitative Disclosures About Market Risk
"	Controls and Procedures
"	Legal Proceedings
"	Risk Factors
"	Unregistered Sales of Equity Securities and Use of Proceeds
"	Exhibits
"	Signatures

iX:

10-Q

i false i 0.01 i 0.01 i 0.01 i 0.01 i 2020 i Q1 i 0000893949 i --12-31Due to a loss from continuing operations for the three months ended March 31, 2020, no incremental shares are included because the effect would be antidilutive.Presented within retained earnings on the consolidated balance sheet as the balance is immaterial. 0000893949 2020-01-01 2020-03-31 0000893949 2020-03-31 0000893949 2019-12-31 0000893949 2019-01-01 2019-03-31 0000893949 2018-08-31 0000893949 2020-05-01 0000893949 2018-12-31 0000893949 2019-03-31 0000893949 md:AmendedAndRestatedTwoThousandEightPlanMember us-gaap:EmployeeStockOptionMember 2020-03-31 0000893949 md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember 2020-03-31 0000893949 md:UnnamedCorporateJointVentureOneMember 2020-03-31 0000893949 md:UnnamedCorporateJointVentureTwoMember 2020-03-31 0000893949 us-gaap:CashEquivalentsMember 2020-03-31 0000893949 us-gaap:AllOtherCorporateBondsMember 2020-03-31 0000893949 us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-03-31 0000893949 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-03-31 0000893949 us-gaap:CertificatesOfDepositMember 2020-03-31 0000893949 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000893949 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000893949 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000893949 md:TwoThousandTwentyThreeMember 2020-03-31 0000893949 md:TwoThousandTwentySevenMember 2020-03-31 0000893949 md:NorthAmericanPartnersInAnesthesiaMember 2020-03-31 0000893949 us-gaap:CashEquivalentsMember 2019-12-31 0000893949 us-gaap:AllOtherCorporateBondsMember 2019-12-31 0000893949 us-gaap:USStatesAndPoliticalSubdivisionsMember 2019-12-31 0000893949 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000893949 us-gaap:CertificatesOfDepositMember 2019-12-31 0000893949 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000893949 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000893949 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000893949 md:TwoThousandTwentySevenMember 2019-12-31 0000893949 md:TwoThousandTwentyThreeMember 2019-12-31 0000893949 us-gaap:HealthCarePatientServiceMember 2020-01-01 2020-03-31 0000893949 md:HospitalsContractsMember 2020-01-01 2020-03-31 0000893949 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-03-31 0000893949 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0000893949 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000893949 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0000893949 md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember 2020-01-01 2020-03-31 0000893949 md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember 2020-01-01 2020-03-31 0000893949 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000893949 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000893949 md:ContractedManagedCareMember 2020-01-01 2020-03-31 0000893949 us-gaap:GovernmentMember 2020-01-01 2020-03-31 0000893949 us-gaap:ThirdPartyPayorMember 2020-01-01 2020-03-31 0000893949 us-gaap:SelfPayMember 2020-01-01 2020-03-31 0000893949 md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember 2020-01-01 2020-03-31 0000893949 md:AmendedAndRestatedTwoThousandEightPlanMember us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0000893949 us-gaap:DiscontinuedOperationsHeldforsaleMember 2020-01-01 2020-03-31 0000893949 srt:ExecutiveOfficerMember md:CovidNinenteenMember 2020-01-01 2020-03-31 0000893949 md:NorthAmericanPartnersInAnesthesiaMember 2020-01-01 2020-03-31 0000893949 md:Seniorunsecurdnotes2023Member 2020-01-01 2020-03-31 0000893949 md:Seniorunsecurdnotes2027Member 2020-01-01 2020-03-31 0000893949 us-gaap:HealthCarePatientServiceMember 2019-01-01 2019-03-31 0000893949 md:HospitalsContractsMember 2019-01-01 2019-03-31 0000893949 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-03-31 0000893949 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000893949 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000893949 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000893949 md:ContractedManagedCareMember 2019-01-01 2019-03-31 0000893949 us-gaap:GovernmentMember 2019-01-01 2019-03-31 0000893949 us-gaap:ThirdPartyPayorMember 2019-01-01 2019-03-31 0000893949 us-gaap:SelfPayMember 2019-01-01 2019-03-31 0000893949 us-gaap:DiscontinuedOperationsHeldforsaleMember 2019-01-01 2019-03-31 0000893949 md:ForecastForSecondAndThirdQuartersOf2020Member md:CreditAgreementMember 2020-03-25 0000893949 md:CreditAgreementMember md:ForecastForSecondQuarterOf2021Member 2020-03-25 0000893949 md:CovidNinenteenMember 2020-03-27 2020-03-27 0000893949 md:CovidNinenteenMember 2020-03-27 0000893949 md:CovidNinenteenMember md:RuralAreaMember 2020-04-01 0000893949 md:CovidNinenteenMember md:UrbanAreaMember 2020-04-01 0000893949 md:CovidNinenteenMember 2020-04-01 0000893949 md:CreditAgreementMember md:ForecastForSecondAndThirdQuartersOf2020Member srt:MinimumMember 2020-03-25 2020-03-25 0000893949 md:CreditAgreementMember md:ForecastForSecondAndThirdQuartersOf2020Member srt:MaximumMember 2020-03-25 2020-03-25 0000893949 md:CreditAgreementMember md:ForecastForFourthQuarterOf2020Member 2020-03-25 2020-03-25 0000893949 md:CreditAgreementMember md:ForecastForFirstQuarterOf2021Member 2020-03-25 2020-03-25 0000893949 us-gaap:SubsequentEventMember md:NorthAmericanPartnersInAnesthesiaMember 2020-05-06 0000893949 us-gaap:SubsequentEventMember md:NorthAmericanPartnersInAnesthesiaMember srt:MinimumMember 2020-05-06 0000893949 us-gaap:SubsequentEventMember md:NorthAmericanPartnersInAnesthesiaMember srt:MaximumMember 2020-05-06 0000893949 us-gaap:SubsequentEventMember md:NorthAmericanPartnersInAnesthesiaMember 2020-05-06 2020-05-06 0000893949 us-gaap:SubsequentEventMember md:NorthAmericanPartnersInAnesthesiaMember srt:MinimumMember 2020-05-06 2020-05-06 0000893949 us-gaap:SubsequentEventMember md:NorthAmericanPartnersInAnesthesiaMember srt:MaximumMember 2020-05-06 2020-05-06 0000893949 us-gaap:CommonStockMember 2019-12-31 0000893949 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000893949 us-gaap:RetainedEarningsMember 2019-12-31 0000893949 us-gaap:CommonStockMember 2020-03-31 0000893949 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000893949 us-gaap:RetainedEarningsMember 2020-03-31 0000893949 us-gaap:CommonStockMember 2018-12-31 0000893949 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000893949 us-gaap:RetainedEarningsMember 2018-12-31 0000893949 us-gaap:CommonStockMember 2019-03-31 0000893949 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000893949 us-gaap:RetainedEarningsMember 2019-03-31 iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

i 10-Q

i ☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended i March 31, 2020

i ☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______

Commission File Number:

i 001-12111

i MEDNAX, INC.

(Exact name of registrant as specified in its charter)


i Florida		i 26-3667538
(State or other jurisdiction of Incorporation or organization)		(I.R.S. Employer Identification No.)

i 1301 Concord Terrace i Sunrise, i Florida		i 33323
(Address of principal executive offices)		(Zip Code)

( i 954)

i 384-0175

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
i Common Stock, par value $.01 per share	i MD	i New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

i Yes

☑

☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T

(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). i Yes

☑

☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule

12b-2

of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act). Yes

☐

i ☑

May

, 2020, the registrant had outstanding i 85,409,248 shares of Common Stock, par value $.01 per share.

Table of Contents

MEDNAX, INC.

INDEX


		Page
PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements		3

	Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 (Unaudited)		3

	Consolidated Statements of Income for the Three Months Ended March 31, 2020 and 2019 (Unaudited)		4

	Consolidated Statements of Equity for the Three Months Ended March 31, 2020 and 2019 (Unaudited)		5

	Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019 (Unaudited)		6

	Notes to Consolidated Financial Statements (Unaudited)		7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		14

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		22

Item 4.	Controls and Procedures		22

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings		23

Item 1A.	Risk Factors		23

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		24

Item 6.	Exhibits		25

SIGNATURES			26

Table of Contents

MEDNAX, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands)

(Unaudited)


	March 31, 2020			December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents	$	i 312,155		$	i 112,767
Short-term investments		i 85,041			i 74,510
Accounts receivable, net		i 476,991			i 498,869
Prepaid expenses		i 19,409			i 21,919
Income taxes receivable		i 26,449			i —
Other current assets		i 20,851			i 23,442

Total current assets		i 940,896			i 731,507
Property and equipment, net		i 100,227			i 94,492
Goodwill		i 2,710,292			i 2,710,292
Intangible assets, net		i 263,308			i 274,407
Operating lease right-of-use assets		i 79,810			i 82,824
Deferred income tax assets		i 132,783			i 162,385
Other assets		i 92,346			i 89,994

Total assets	$	i 4,319,662		$	i 4,145,901

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	i 323,363		$	i 511,866
Current portion of finance lease liabilities		i 697			i 130
Current portion of operating lease liabilities		i 22,340			i 23,317
Income taxes payable		i —			i 6,505

Total current liabilities		i 346,400			i 541,818
Line of credit		i 368,500			i —
Long-term debt and finance lease liabilities, net		i 1,733,469			i 1,730,295
Long-term operating lease liabilities		i 62,238			i 67,005
Long-term professional liabilities		i 238,347			i 226,892
Deferred income tax liabilities		i 61,975			i 57,995
Other liabilities		i 21,337			i 22,900

Total liabilities		i 2,832,266			i 2,646,905

Commitments and contingencies			i			i
Shareholders’ equity:
Preferred stock; $.01 par value; i i 1,000 / shares authorized; i i none / issued		i —			i —
Common stock; $.01 par value; i i 200,000 / shares authorized; i i 85,150 / and i i 84,248 / shares issued and outstanding, respectively		i 852			i 842
Additional paid-in capital		i 995,257			i 987,942
Retained earnings		i 491,287			i 510,212

Total shareholders’ equity		i 1,487,396			i 1,498,996

Total liabilities and shareholders’ equity	$	i 4,319,662		$	i 4,145,901

The accompanying notes are an integral part of these Consolidated Financial Statements.

Table of Contents

MEDNAX, INC.

CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

(Unaudited)


	Three Months Ended March 31,
	2020			2019
Net revenue	$	i 845,918		$	i 851,183

Operating expenses:
Practice salaries and benefits		i 652,721			i 621,539
Practice supplies and other operating expenses		i 25,264			i 25,791
General and administrative expenses		i 105,235			i 101,821
Depreciation and amortization		i 18,673			i 20,033
Transformational and restructuring related expenses		i 30,907			i 3,544

Total operating expenses		i 832,800			i 772,728

Income from operations		i 13,118			i 78,455
Investment and other (expense) income		( i 679	)		i 1,647
Interest expense		( i 27,608	)		( i 30,723	)
Equity in earnings of unconsolidated affiliates		i 1,345			i 1,236

Total non-operating expenses		( i 26,942	)		( i 27,840	)

(Loss) income from continuing operations before income taxes		( i 13,824	)		i 50,615
Income tax provision		( i 2,286	)		( i 8,962	)

(Loss) income from continuing operations		( i 16,110	)		i 41,653
Loss from discontinued operations, net of tax		( i 2,602	)		( i 284,525	)

Net loss	$	( i 18,712	)	$	( i 242,872	)

Per common and common equivalent share data:
(Loss) income from continuing operations:
Basic	$	( i 0.20	)	$	i 0.48

Diluted	$	( i 0.20	)	$	i 0.48

Loss from discontinued operations:
Basic	$	( i 0.03	)	$	( i 3.31	)

Diluted	$	( i 0.03	)	$	( i 3.29	)

Net loss:
Basic	$	( i 0.23	)	$	( i 2.82	)

Diluted	$	( i 0.23	)	$	( i 2.81	)

Weighted average common shares:
Basic		i 82,799			i 86,073
Diluted		i 82,799			i 86,545

The accompanying notes are an integral part of these Consolidated Financial Statements.

Table of Contents

MEDNAX, INC.

CONSOLIDATED STATEMENTS OF EQUITY

(in thousands)


	Common Stock
	Number of Shares			Amount			Additional Paid-in Capital			Retained Earnings			Total Equity
2020
Balance at January 1, 2020		i 84,248		$	i 842		$	i 987,942		$	i 510,212		$	i 1,498,996

Net loss		—			—			—			( i 18,712	)		( i 18,712	)
Unrealized holding loss on investments, net of tax (1)		—			—			—			( i 213	)		( i 213	)
Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan		i 78			i 1			i 1,831			—			i 1,832
Issuance of restricted stock		i 968			i 10			( i 10	)		—			—
Forfeitures of restricted stock		( i 19	)		—			—			—			—
Stock-based compensation expense		—			—			i 8,035			—			i 8,035
Repurchased common stock		( i 125	)		( i 1	)		( i 2,541	)		i —			( i 2,542	)

Balance at March 31, 2020		i 85,150		$	i 852		$	i 995,257		$	i 491,287		$	i 1,487,396

2019
Balance at January 1, 2019		i 87,820		$	i 878		$	i 992,647		$	i 2,094,359		$	i 3,087,884

Net loss		—			—			—			( i 242,872	)		( i 242,872	)
Unrealized holding loss on investments, net of tax (1)		—			—			—			( i 194	)		( i 194	)
Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan		i 140			i 1			i 3,541			—			i 3,542
Issuance of restricted stock		i 978			i 10			( i 10	)		—			—
Forfeitures of restricted stock		( i 6	)		—			—			—			—
Stock swaps		( i 20	)		—			( i 666	)		—			( i 666	)
Stock-based compensation expense		—			—			i 11,100			—			i 11,100
Repurchased common stock		( i 2,525	)		( i 25	)		( i 28,740	)		( i 50,217	)		( i 78,982	)

Balance at March 31, 2019		i 86,387		$	i 864		$	i 977,872		$	i 1,801,076		$	i 2,779,812

(1)	Presented within retained earnings on the consolidated balance sheet as the balance is immaterial.

The accompanying notes are an integral part of these Consolidated Financial Statements.

Table of Contents

MEDNAX, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)


	Three Months Ended March 31,
	2020			2019
Cash flows from operating activities:
Net income (loss)	$	( i 18,712	)	$	( i 242,872	)
Loss from discontinued operations		i 2,602			i 284,525
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization		i 18,673			i 20,033
Amortization of premiums, discounts and issuance costs		i 1,458			i 1,520
Stock-based compensation expense		i 8,035			i 10,989
Deferred income taxes		i 33,582			( i 5,108	)
Other		( i 1,883	)		i 2,767
Changes in assets and liabilities:
Accounts receivable		i 25,904			( i 15,915	)
Prepaid expenses and other current assets		i 5,101			i 4,790
Other long-term assets		i 11,189			i 9,580
Accounts payable and accrued expenses		( i 198,452	)		( i 132,559	)
Income taxes payable		( i 32,883	)		i 14,373
Payments of contingent consideration liabilities		( i 102	)		( i 42	)
Long-term professional liabilities		i 6,969			( i 496	)
Other liabilities		( i 7,912	)		( i 11,993	)

Net cash used in operating activities – continuing operations		( i 146,431	)		( i 60,408	)
Net cash provided by operating activities - discontinued operations		i —			i 3,591

Net cash used in operating activities		( i 146,431	)		( i 56,817	)

Cash flows from investing activities:
Acquisition payments, net of cash acquired		( i 75	)		( i 4,250	)
Purchases of investments		( i 21,042	)		i —
Proceeds from maturities or sales of investments		i 9,860			i 4,800
Purchases of property and equipment		( i 13,713	)		( i 5,821	)
Proceeds from sale of business		i 4,750			i —

Net cash used in investing activities – continuing operations		( i 20,220	)		( i 5,271	)
Net cash used in investing activities - discontinued operations		i —			( i 3,420	)

Net cash used in investing activities		( i 20,220	)		( i 8,691	)

Cash flows from financing activities:
Borrowings on credit agreement		i 515,000			i 518,500
Payments on credit agreement		( i 146,500	)		( i 866,000	)
Proceeds from issuance of senior notes		i —			i 500,000
Payments for credit facility amendment and financing costs		( i 500	)		( i 8,380	)
Payments of contingent consideration liabilities		( i 1,248	)		( i 1,308	)
Payments on finance lease obligations		( i 3	)		( i 42	)
Proceeds from issuance of common stock		i 1,832			i 2,876
Repurchases of common stock		( i 2,542	)		( i 78,982	)

Net cash provided from financing activities – continuing operations		i 366,039			i 66,664
Net cash provided from financing activities - discontinued operations		i —			i —

Net cash provided from financing activities		i 366,039			i 66,664

Net increase in cash and cash equivalents		i 199,388			i 1,156
Cash and cash equivalents at beginning of period		i 112,767			i 56,745
Less cash and cash equivalents of discontinued operations at end of period		i —			( i 11,425	)

Cash and cash equivalents of continuing operations at end of period	$	i 312,155		$	i 46,476

The accompanying notes are an integral part of these Consolidated Financial Statements.

Table of Contents

MEDNAX, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(Unaudited)

1.	Basis of Presentation and New Accounting Pronouncements:

The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form

10-Q

have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of MEDNAX, Inc. and its consolidated subsidiaries (collectively, “MDX”) together with the accounts of MDX’s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the “affiliated professional contractors”). Certain subsidiaries of MDX have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms “MEDNAX” and the “Company” refer collectively to MEDNAX, Inc., its subsidiaries and the affiliated professional contractors.

The Company is a party to a joint venture in which it owns a i 37.5% economic interest and a second joint venture in which it owns a i 49.0% economic interest. The Company accounts for these joint ventures under the equity method of accounting because the Company exercises significant influence over, but does not control, these entities.

The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company’s most recent Annual Report on Form

10-K

(the “Form

10-K”).

In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData were reported as discontinued operations in the Company’s Consolidated Statements of Income for the three months ended March 31, 2019. See note 6 for more information.

New Accounting Pronouncements

In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on

step-up

in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain

year-to-date

loss limitations. The guidance becomes effective for the Company on January 1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures.

2.	Coronavirus Pandemic (“COVID-19”):

COVID-19

and related “stay at home” and social distancing measures implemented across the country has significantly impacted demand for medical services provided by the Company’s affiliated clinicians. Beginning in

mid-March

2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where the Company’s affiliated clinicians provided anesthesia services. See Note 12 - Subsequent Events for information regarding the divestment of the Company’s anesthesia medical group on May 6, 2020. Much of this decline has been due to the closure of operating suites or facilities following federal advisories to cancel

non-urgent

procedures and the prohibition of such procedures by several states. Within the Company’s radiology service line, orders for radiological studies have declined by a meaningful amount from historically normal levels, with much of this reduction focused in

non-urgent

studies. The Company’s affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, have seen a significant elevation of appointment cancellations compared to historical normal levels. At this time, the Company has not experienced, nor does it currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of

COVID-19.

The Company has implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of

COVID-19.

These steps included a suspension of most activities related to the Company’s transformational and restructuring programs, limiting these expenditures to those that

provide

essential support for the Company’s response to

COVID-19.

In addition, (i) the Company temporarily reduced executive and key management base salaries, including i 50% reductions in salaries for its named executive officers through at least June 30, 2020; (ii) the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, until further notice; (iii) the Company enacted a combination of salary reductions and furloughs for

non-clinical

employees; and (iv) the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations.

In response to the anticipated impact of COVID-19 on the Company’s results of operations, on

March 25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i) establish a deemed Consolidated EBITDA of $ i 139.2 million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the

Table of Contents

calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii) temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from i 4.50:1:00 to i 5.00:1:00 for the second and third quarters of 2020 and i 4.75:1:00 for the fourth quarter of i 2020, before returning to

4.50:1:00

for the first quarter of 2021 and beyond, (iii) require that the Company maintains minimum availability under the Credit Agreement of $ i 300.0 million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $ i 300.0 million, plus a reserve for certain payables, and (v) temporarily restrict the Company’s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain

exceptions. At March 31, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its i 5.25% senior unsecured notes due 2023 and its i 6.25% senior unsecured notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve months.

CARES Act

On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $ i 100 billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to

COVID-19.

The Department of Health and Human Services (“HHS”) is administering this program and began disbursing funds from the initial $ i 30 billion in early April 2020, of which the Company’s affiliated physician practices received an aggregate of $ i 12.2 million based on their respective share of Medicare fee for service reimbursements in 2019. The remaining $ i 70 billion in aid is intended to focus on providers in areas particularly impacted by

COVID-19,

rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive.

In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with i 50% of the deferred amount due December 31, 2021 and the remaining i 50% due December 31, 2022. The Company intends to utilize this deferral option throughout 2020.

The Company currently expects that the COVID-19 situation will materially impact its financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from COVID-19, the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months.

Table of Contents

3.	Cash Equivalents and Investments:

As of March 31, 2020 and December 31, 2019, the Company’s cash equivalents consisted entirely of money market funds totaling $ i 6.4 million and $ i 16.8 million, respectively. Investments consisted of corporate securities, municipal debt securities, federal home loan securities and certificates of deposit. All investments are classified as current.

Investments held at March 31, 2020 and December 31, 2019 are summarized as follows (in thousands):


	March 31, 2020		December 31, 2019
Corporate securities	$	i 46,883	$	i 32,962
Municipal debt securities		i 23,327		i 29,066
Federal home loan securities		i 8,052		i 8,013
Certificates of deposit		i 6,779		i 4,469

	$	i 85,041	$	i 74,510

/ / i

4.	Fair Value Measurements:

The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:

Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.

The following table presents information about the Company’s financial instruments that are accounted for at fair value on a recurring basis at March 31, 2020 and December 31, 2019 (in thousands):

Fair Value

Fair Value
Category

March 31, 2020

December 31, 2019

Assets:

Money market funds

Level 1

i 6,357

i 16,775

Short-term investments

Level 2

i 85,041

i 74,510

Mutual Funds

Level 1

i 11,640

i 14,264

Liabilities:

Contingent consideration

Level 3

i 1,288

i 2,696

/ i

The following table presents information about the Company’s financial instruments that are not carried at fair value at March 31, 2020 and December 31, 2019 (in thousands):

March 31, 2020

December 31, 2019

Carrying
Amount

Fair

Value

Carrying
Amount

Fair

Value

Liabilities:

2023 Notes

i 750,000

i 611,250

i 750,000

i 766,875

2027 Notes

i 1,000,000

i 801,200

i 1,000,000

i 1,025,600

The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the Company’s line of credit approximates fair value. If the line of credit was measured at fair value, it would be

categorized as Level 2 in the fair value hierarchy.

Table of Contents

5 .	Accounts Receivable and Net Revenue:

Accounts receivable, net consists of the following (in thousands):


	March 31, 2020			December 31, 2019
Gross accounts receivable	$	i 1,840,118		$	i 1,943,664
Allowance for contractual adjustments and uncollectibles		( i 1,363,127	)		( i 1,444,795	)

	$	i 476,991		$	i 498,869

Patient service revenue is recognized at the time services are provided by the Company’s affiliated physicians. The Company’s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company’s patient service revenue is reimbursed by government-sponsored healthcare programs (“GHC Programs”) and third-party insurance payors. Payments for services rendered to the Company’s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.

Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (“DSO”) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.

Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.

Some of the Company’s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.

The following table summarizes the Company’s net revenue by category (in thousands):


	Three Months Ended March 31,
	2020		2019
Net patient service revenue	$	i 734,387	$	i 749,585
Hospital contract administrative fees		i 104,595		i 94,721
Other revenue		i 6,936		i 6,877

	$	i 845,918	$	i 851,183

/ i

The approximate percentage of net patient service revenue by type of payor was as follows:


	Three Months Ended March 31,
	2020			2019
Contracted managed care		i 68	%		i 69	%
Government		i 25			i 24
Other third-parties		i 5			i 5
Private-pay patients		i 2			i 2

		i 100	%		i 100	%

/ /

6 .	Discontinued Operations:

On October 10, 2019, the Company entered into a securities purchase agreement with an affiliate of Frazier Healthcare Partners to divest its management services organization, which operated as MedData, and the transaction closed on October 31, 2019. The operating results of the management services service line were reported as discontinued operations in the Company’s Consolidated Statements of Income for the three months ended March 31, 2019. Loss from discontinued operations, net of income taxes, as reported in the Company’s Consolidated Statements of Income for the three months ended March 31, 2019

was $ i 284.5 million

which included a loss on classification as held for sale of $ i 321.2 million.

Table of Contents

During the three months ended March 31, 2020,

the

Company recorded an incremental loss on the sale of MedData

of $ i 3.6 million, primarily related to the finalization of certain transaction related expenses of $ i 5.1 million and a working capital

true-up

of $ i 0.2 million, partially offset by the completion of its preliminary valuation for the contingent economic consideration

which decreased the loss on sale by $ i 1.7 million.

7.	Accounts Payable and Accrued Expenses:

Accounts payable and accrued expenses consist of the following (in thousands):


	March 31, 2020		December 31, 2019
Accounts payable	$	i 47,519	$	i 39,610
Accrued salaries and bonuses		i 108,079		i 268,619
Accrued payroll taxes and benefits		i 47,791		i 67,268
Accrued professional liabilities		i 48,149		i 44,869
Accrued contingent consideration		i 1,288		i 2,696
Accrued interest		i 27,422		i 32,910
Other accrued expenses		i 43,115		i 55,894

	$	i 323,363	$	i 511,866

The net decrease in accrued salaries and bonuses of $ i 160.5 million, from December 31, 2019 to March 31, 2020, is primarily due to the payment of performance-based incentive compensation, principally to the Company’s affiliated physicians, partially offset by performance-based incentive compensation accrued during the three months ended March 31, 2020. A majority of the Company’s payments for performance-based incentive compensation is paid annually during the first quarter.

8 .	Common and Common Equivalent Shares:

Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method.

The calculation of shares used in the basic and diluted net income per common share calculation for the three months ended March 31, 2020 and 2019 is as follows (in thousands):


	Three Months Ended March 31,
	2020		2019
Weighted average number of common shares outstanding		i 82,799		i 86,073
Weighted average number of dilutive common share equivalents		—		i 472

Weighted average number of common and common equivalent shares outstanding (a)		i 82,799		i 86,545

Antidilutive securities not included in the diluted net income per common share calculation		i 849		i 504

(a)

Due to a loss from continuing operations for the three months ended March 31, 2020, no incremental shares are included because the effect would be antidilutive.

9 .	Stock Incentive Plans and Stock Purchase Plans:

The Company’s Amended and Restated 2008 Incentive Compensation Plan (the “Amended and Restated 2008 Incentive Plan”) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.

Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within i 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of i three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the three months ended March 31, 2020, the Company granted i 894,718 shares of restricted stock to its employees and

non-employee

directors under the Amended and Restated 2008 Incentive Plan. At March 31, 2020, the Company had i 6.6

million

shares available for future grants and awards under

the

Amended and Restated 2008 Incentive Plan.

Under the Company’s 1996

Non-Qualified

Employee Stock Purchase Plan, as amended (the “ESPP”), employees are permitted to purchase the Company’s common stock at i 85% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company’s 2015

Non-Qualified

Stock Purchase Plan (the “SPP”), certain eligible

non-employee

service providers are permitted to purchase the Company’s common stock at i 90% of market value on January 1st, April 1st, July 1st and October 1st of each year.

Table of Contents

Each of the ESPP and the SPP provide for the issuance of an aggregate of i 2.6 million shares of the Company’s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and

non-employee

service providers. During the three months ended March 31, 2020, approximately i 78,300 shares in aggregate were issued under the ESPP and SPP. At March 31, 2020, the Company had approximately i 1.0 million shares in aggregate reserved for issuance under the ESPP and SPP.

During the three months ended March 31, 2020 and 2019, the Company recognized stock-based compensation expense of $ i 7.8 million and $ i 11.0 million, respectively.

10 .	Common Stock Repurchase Programs:

In July 2013, the Company’s Board of Directors authorized the repurchase of shares of the Company’s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company’s equity compensation programs. The share repurchase program allows the Company to make open market purchases from

time-to-time

based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company’s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company’s acquisition program. No shares were purchased under this program during the three months ended March 31, 2020.

In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $ i 500.0 million of the Company’s common stock in addition to its existing share repurchase program, of which $ i 107.2 million remained available

for repurchase as of December 31, 2019. Under this share repurchase program, during the three months ended March 31, 2020,

the Company withheld

i 125,100

shares of

its

common stock to satisfy minimum statutory withholding obligations of $

i 2.5

million in connection with the vesting of restricted stock.

The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.

11 .	Commitments and Contingencies:

The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of March 31, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.

In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company’s affiliated physicians. The Company’s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company’s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows and the trading price of its securities.

Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company’s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows and the trading price of its securities.

Table of Contents

12.	Subsequent Event:

On May 6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (“NAPA”) to divest of the Company’s anesthesiology medical group, and the transaction closed on May 6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment

of $

i 50.0

million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $ i 0 to $ i 250 million based upon the multiple of invested capital returned to NAPA’s owners upon exit of the investment. The Company will begin to receive a payment on its economic interest at an exit multiple of 2.0, with such payment reaching

i 250

million at an exit multiple of 5.0. In addition, the Company retained the accounts receivable of the anesthesiology medical group, which net of various other working capital items, approximated

i 110.0

million at March 31, 2020. Upon completion of a valuation to determine the final net proceeds, the Company anticipates recording a loss on disposal in the range of approximately

i 500.0

million to $

i 600.0

million.

The following table represents the major classes of assets and liabilities of the anesthesiology medical group that are included in the accompanying Consolidated Balance Sheets as of March 31, 2020 (in thousands):


	March 31, 2020
Assets
Cash and cash equivalents	$	i 19
Accounts receivable, net		i 147,717
Prepaid expenses and other assets		i 14,519
Property and equipment, net		i 900
Goodwill		i 545,272
Intangible assets, net		i 60,034

	$ i 768,461

Liabilities
Accounts payable and accrued expenses	$	i 54,311
Accrued professional liabilities		i 20,627
Other liabilities		i 5,174

	$ i 80,112

/ /

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form

10-K

for the fiscal year ended December 31, 2019, filed with the Securities and Exchange Commission on February 20, 2020 (the “2019 Form

10-K”).

As used in this Quarterly Report, the terms “MEDNAX”, the “Company”, “we”, “us” and “our” refer to the parent company, MEDNAX, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, “MDX”), together with MDX’s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (“affiliated professional contractors”). Certain subsidiaries of MDX have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The following discussion contains forward-looking statements. Please see the Company’s 2019 Form

10-K,

including Item 1A, Risk Factors, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see “Caution Concerning Forward-Looking Statements” below.

Overview

MEDNAX is a leading provider of physician services including newborn, maternal-fetal, radiology and teleradiology, pediatric cardiology and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in all 50 states, the District of Columbia and Puerto Rico. Our affiliated physicians provide neonatal clinical care, primarily within hospital-based neonatal intensive care units, to babies born prematurely or with medical complications; radiology services including diagnostic imaging and interventional radiology; and maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including those who provide pediatric intensive care, pediatric cardiology care, hospital-based pediatric care, pediatric surgical care, pediatric ear, nose and throat, pediatric ophthalmology and pediatric urology services. MEDNAX also provides radiology services including diagnostic imaging and interventional radiology, through a network of affiliated physicians, as well as teleradiology services through a network of affiliated radiologists. In addition to our national physician network, we provide services nationwide to healthcare facilities and physicians, including ours, through a consulting services company. MEDNAX divested its anesthesia medical group on May 6, 2020.

Coronavirus Pandemic

(COVID-19)

COVID-19

and related “stay at home” and social distancing measures implemented across the country have significantly impacted demand for medical services provided by our affiliated clinicians. Beginning in

mid-March

2020, we experienced a significant decline in the number of elective surgeries at the facilities where our affiliated clinicians provided anesthesia services. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel

non-urgent

procedures and the prohibition of such procedures by several states. Within our radiology service line, orders for radiological studies have declined by a meaningful amount from historically normal levels, with much of this reduction focused in

non-urgent

studies. Our affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, have seen a significant elevation of appointment cancellations compared to historical normal levels. At this time, we have not experienced, nor do we currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of

COVID-19.

We have implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of

COVID-19.

These steps included a suspension of most activities related to our transformational and restructuring programs, limiting these expenditures to those that provide essential support for our response to

COVID-19.

In addition, (i) we temporarily reduced executive and key management base salaries, including 50% reductions in salaries for our named executive officers through at least June 30, 2020; (ii) our Board of Directors agreed to forego their annual cash retainer and cash meeting payments, until further notice; (iii) we enacted a combination of salary reductions and furloughs for

non-clinical

employees; and (iv) we enacted significant operational and practice-specific expense reduction plans across our clinical operations.

We have also implemented a variety of solutions across specialties to support clinicians and patients during this pandemic, including

•

Clinician Shortage Support

Pediatric clinicians are lending their expertise to help fulfill the need for added adult care.

•

Strengthening of Supply Chain

MEDNAX is helping to address the shortage of personal protective equipment (PPE) by partnering with vendors across industries to source high filtration respirators, surgical masks and other forms of PPE for protective use.

Table of Contents

•

Expanded Virtual Care Offerings

Utilizing VSee, an internationally recognized telehealth platform, MEDNAX has deployed a national multi-specialty virtual clinic to expand its telehealth offerings and make virtual care available to its clinical workforce, enabling continued patient consults and clinician collaboration while minimizing

COVID-19

exposure.

•

Early Virus Detection Using Cutting-Edge Imaging Diagnostic Tools

MEDNAX Radiology Solutions is leading early detection efforts through chest imaging. vRad, a MEDNAX company, diagnosed one of the first

COVID-19

patients in the United States via chest computed tomography (“CT”), which showed findings consistent with a severe acute respiratory viral infection. In the absence of laboratory testing kits, chest CT can serve as a diagnostic tool. In addition, MEDNAX Radiology Solutions is refining natural language processing (“NLP”) to identify the incidence of viral pneumonia and typical findings of the

COVID-19

virus in the lungs via chest CT across the proprietary MEDNAX Imaging Platform and inference engine, which is connected to more than 2,000 partner facilities across the country. The NLP is run retrospectively to monitor the amount and rate of increase of suspected chest CT findings for

COVID-19

and viral pneumonia, supporting faster treatment. If successful, this cutting-edge diagnostic tool could serve as an effective tracker of the disease’s progression throughout the country and provide new insights for imaging findings for

COVID-19

patients.

•

Virtual Forum to Provide Clinician Support

To support frontline clinicians while abiding by social distancing recommendations, MEDNAX has created a virtual doctors’ lounge for clinicians across specialties to connect and socialize in the absence of typical

in-person

lounges, helping to boost morale and preserve a sense of normalcy.

We currently expect that

COVID-19

will materially impact our financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from

COVID-19,

we are unable to predict the ultimate impact on our business, financial condition, results of operations, cash flows and the trading price of our securities at this time.

CARES Act

On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100 billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to

COVID-19.

The Department of Health and Human Services (“HHS”) is administering this program and began disbursing funds from the initial $30 billion in early April 2020, of which our affiliated physician practices received an aggregate of $12.2 million based on their respective share of Medicare fee for service reimbursements in 2019. The remaining $70 billion in aid is intended to focus on providers in areas particularly impacted by

COVID-19,

rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act we and our affiliated physician practices will qualify for and receive.

In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December 31, 2021 and the remaining 50% due December 31, 2022. We intend to utilize this deferral option throughout 2020.

General Economic Conditions and Other Factors

Our operations and performance depend significantly on economic conditions. During the three months ended March 31, 2020, the percentage of our patient service revenue being reimbursed under government-sponsored healthcare programs (“GHC Programs”) remained relatively consistent as compared to the three months ended March 31, 2019. Economic conditions in the United States (“U.S.”) have deteriorated, primarily as a result of

COVID-19,

and patient volumes have declined. We could also experience additional shifts toward GHC Programs if changes occur in population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, due to the rising costs of managed care premiums and patient responsibility amounts, we may experience lower net revenue resulting from increased bad debt due to patients’ inability to pay for certain services.

Transformation and Restructuring Initiatives

We have developed a number of strategic initiatives across our organization, in both our shared services functions and our operational infrastructure, with a goal of generating improvements in our general and administrative expenses and our operational infrastructure. We have broadly classified these workstreams in four broad categories including practice operations, revenue cycle management, information technology and human resources. We have included the expenses, which in certain cases represent estimates, related to such activity on a separate line item in our consolidated statements. In our shared services departments, we were focused on improving processes, using our resources more efficiently and utilizing our scale more effectively to improve cost and service performance across our operations. Within our operational infrastructure, we developed specific operational plans within each of our service lines and affiliated physician practices, with specific milestones and regular reporting, with the goal of generating long-term operational improvements and fostering even greater collaboration across our national medical group. We intended to make a series of information-technology and other investments to improve processes and performance across our enterprise, using both internal and external resources. We believed these strategic initiatives, together with our

continued plans to invest in focused, targeted and strategic organic and acquisitive growth, positioned us well to deliver a differentiated value proposition to our stakeholders while continuing to provide the highest quality care for our patients.

Table of Contents

We originally expected these activities to continue through at least 2020. However, as discussed above, beginning in April 2020, we reduced the scope of our transformation and restructuring related initiatives unless they are initiatives that provide essential support for our response to

COVID-19.

Healthcare Reform

The Patient Protection and Affordable Care Act (the “ACA”) contains a number of provisions that have affected us and, absent amendment or repeal, may continue to affect us over the next several years. These provisions include the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions have expanded the scope and reach of the Federal Civil False Claims Act and other healthcare fraud and abuse laws. Moreover, we could be affected by potential changes to various aspects of the ACA, including changes to subsidies, healthcare insurance marketplaces and Medicaid expansion.

The ACA remains subject to continuing legislative and administrative flux and uncertainty. In 2017, Congress unsuccessfully sought to replace substantial parts of the ACA with different mechanisms for facilitating insurance coverage in the commercial and Medicaid markets. Congress may again attempt to enact substantial or target changes to the ACA in the future. Additionally, Centers for Medicare & Medicaid Services (“CMS”) has administratively revised a number of provisions and may seek to advance additional significant changes through regulation, guidance and enforcement in the future.

At the end of 2017, Congress repealed the part of the ACA that required most individuals to purchase and maintain health insurance or face a tax penalty, known as the individual mandate. In light of these changes, in December 2018, a federal district court in Texas declared that key portions of the ACA were inconsistent with the U.S. Constitution and that the entire ACA is invalid as a result. Several states appealed this decision, and in December 2019, a federal court of appeals upheld the district court’s conclusion that part of the ACA is unconstitutional but remanded for further evaluation whether in light of this defect the entire ACA must be invalidated. These legal proceedings are likely to continue for several years, and the fate of the ACA will be unresolved and uncertain during this period. Actions by the court of appeals or eventually the Supreme Court of the United States could invalidate portions or all of the ACA. Changes resulting from these proceedings could have a material impact on our business. In the meantime, it also is possible that as a result of these actions, enrollment in healthcare exchanges could decline.

In 2020, there will be federal and state elections that could affect which persons and parties occupy the Office of the President of the United States, control one or both chambers of Congress and many states’ governors and legislatures. Some candidates running for President of the United States are proposing sweeping changes to the U.S. healthcare system, including expanding government-funded healthcare insurance options. Any legislative or administrative change to the current healthcare financing system could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities.

If the ACA is repealed or further substantially modified by judicial, legislative or administrative action, or if implementation of certain aspects of the ACA are diluted, delayed or replaced with a “Medicare for All” or single payor system, such repeal, modification or delay may impact our business, financial condition, results of operations, cash flows and the trading price of our securities. We are unable to predict the impact of any repeal, modification or delay in the implementation of the ACA, including the repeal of the individual mandate or implementation of a single payor system, on us at this time.

In addition to the potential impacts to the ACA, there could be changes to other GHC Programs, such as a change to the structure of Medicaid. Congress and the Administration have sought to convert Medicaid into a block grant or to institute “per capita spending caps”, among other things. These changes, if implemented could eliminate the guarantee that everyone who is eligible and applies for benefits would receive them and could potentially give states new authority to restrict eligibility, cut benefits and make it more difficult for people to enroll. Additionally, several states are considering and pursuing changes to their Medicaid programs, such as requiring recipients to engage in employment or education activities as a condition of eligibility for most adults, disenrolling recipients for failure to pay a premium, or adjusting premium amounts based on income.

As a result, we cannot predict with any assurance the ultimate effect of these laws and resulting changes to payments under GHC Programs, nor can we provide any assurance that they will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, any fiscal tightening impacting GHC Programs or changes to the structure of any GHC Programs could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities.

The Medicare Access and CHIP Reauthorization Act

The Medicare Access and CHIP Reauthorization Act (“MACRA”) requires physicians to choose to participate in one of two payment formulas, Merit-Based Incentive Payment System (“MIPS”) or Alternative Payment Models (“APMs”). Beginning in 2020, MIPS allows eligible physicians to receive incentive payments based on the achievement of certain quality and cost metrics, among other measures, and be reduced for those who are underperforming against those same metrics and measures. As an alternative, physicians can choose to participate in an advanced APM, and physicians who are meaningful participants in APMs will receive bonus payments from Medicare pursuant to the law. MACRA also remains subject to review and potential modification by Congress, as well as shifting regulatory requirements established by CMS. We currently anticipate that our affiliated physicians will continue to be eligible to receive bonus payments in 2020 through participation in the MIPS, although the amounts of such bonus payments are not expected to be material. We will continue to operationalize the provisions of MACRA and assess any further changes to the law or additional regulations enacted pursuant to the law.

Table of Contents

We cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that its provisions will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.

Medicaid Expansion

The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state’s historic eligibility levels to 133% of the federal poverty level. To date, 36 states and the District of Columbia have expanded Medicaid eligibility to cover this additional

low-income

patient population, and other states are considering expansion. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level.

“Surprise” Billing Legislation

“Surprise” medical bills arise when an insured patient receives care from an

out-of-network

provider resulting in costs that were not expected by the patient. The bill is a “surprise” either because the patient did not expect to receive care from an

out-of-network

provider, or because their cost-sharing responsibility is higher than the patient expected. For the past several years, state legislatures have been enacting laws that are intended to address the problems associated with surprise billing or balance billing.

More recently, Congress and President Trump have proposed bipartisan solutions to address this circumstance, either by working in tandem with, or in the absence of, applicable state laws. Several committees of jurisdiction in the U.S. House of Representatives and in the U.S. Senate have proposed solutions to address surprise medical bills, but it is unclear whether any of the proposed solutions will become law. In addition, state legislatures and regulatory bodies continue to address and modify existing laws on the same issue. Any state or federal legislation on the topic of surprise billing may have an unfavorable impact on

out-of-network

reimbursement that we receive. In addition, actual or prospective legislative changes in this area may impact, and may have impacted, our ability to contract with private payors at favorable reimbursement rates or remain in contract with such payors.

Although our

out-of-network

revenue is currently not material, we cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that future legislation or regulations will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.

Medicare Sequestration

The Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, required

across-the-board

cuts (“sequestrations”) to Medicare reimbursement rates. These annual reductions of 2%, on average, apply to mandatory and discretionary spending through 2025. Unless Congress acts in the future to modify these sequestrations, Medicare reimbursements will be reduced by 2%, on average, annually. In connection with the CARES Act, the Medicare sequestrations will be suspended beginning on May 1, 2020 through December 31, 2020. Aside from the suspension, the reduction in Medicare reimbursement rates is not expected to have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities.

Non-GAAP

Measures

In our analysis of our results of operations, we use certain

non-GAAP

financial measures. We have incurred and anticipate we will continue to incur certain expenses related to transformational and restructuring related expenses that are expected to be project-based and periodic in nature. In addition, beginning with the first quarter of 2019, we reported MedData as assets held for sale and discontinued operations. Accordingly, beginning with the first quarter of 2019, we began reporting Adjusted earnings before interest, taxes and depreciation and amortization (“EBITDA”) from continuing operations, defined as income (loss) from continuing operations before interest, taxes, depreciation and amortization, and transformational and restructuring related expenses. Adjusted earnings per share (“Adjusted EPS”) from continuing operations has also been further adjusted for these items and beginning with the first quarter of 2019 consists of diluted income (loss) from continuing operations per common and common equivalent share adjusted for amortization expense, stock-based compensation expense and transformational and restructuring related expenses. Adjusted EPS from continuing operations is being further adjusted to reflect the impacts from discrete tax events. Adjusted EBITDA and Adjusted EPS have also been adjusted for the

non-cash

goodwill impairment charge recorded during the third quarter of 2019. Historical periods do not include any material items that meet the current definition of transformational and restructuring related expenses or goodwill impairment, so although we are retrospectively presenting historical periods for the new definitions, we do not reflect any adjustments for these items.

We believe these measures, in addition to income (loss) from continuing operations, net income (loss) and diluted net income (loss) from continuing operations per common and common equivalent share, provide investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis. These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP. In addition, since these

non-GAAP

measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies.

Table of Contents

For a reconciliation of each of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP measures for the three months ended March 31, 2020 and 2019, refer to the tables below (in thousands, except per share data).


	Three Months Ended March 31,
	2020			2019
(Loss) income from continuing operations	$	(16,110	)	$	41,653
Interest expense		27,608			30,723
Income tax provision		2,286			8,962
Depreciation and amortization		18,673			20,033
Transformational and restructuring related expenses		30,907			3,544

Adjusted EBITDA from continuing operations	$	63,364		$	104,915


	Three Months Ended March 31,
	2020						2019
Weighted average diluted shares outstanding	82,799						86,545
(Loss) income from continuing operations and diluted income from continuing operations per share
Adjustments (1) :	$	(16,110	)	$	(0.20	)	$	41,653		$	0.48
Amortization (net of tax of $2,740 and $3,449)		8,220			0.10			9,325			0.11
Stock-based compensation (net of tax of $1,962 and $2,967)		5,885			0.07			8,022			0.09
Transformational and restructuring expenses (net of tax of $7,727 and $957)		23,180			0.28			2,587			0.03
Net impact from discrete tax events		5,077			0.07			(4,791	)		(0.06	)

Adjusted income and diluted EPS from continuing operations	$	26,252		$	0.32		$	56,796		$	0.65

(1)	Effective tax rates of 25.0% and 27.0% were used to calculate the tax effects of the adjustments in March 31, 2020 and 2019, respectively. The effective tax rates used for the three months ended March 31, 2020 and 2019 exclude the impacts from discrete tax events.

Results of Operations

Three Months Ended March 31, 2020 as Compared to Three Months Ended March 31, 2019

Our net revenue attributable to continuing operations was $845.9 million for the three months ended March 31, 2020, as compared to $851.2 million for the same period in 2019. The decrease in revenue of $5.3 million, or 0.6%, was primarily attributable to the unfavorable impacts from

COVID-19

on same-unit revenue. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue declined by $8.1 million, or 1.0%. The decline in same-unit net revenue was comprised of a decrease of $16.3 million, or 2.0%, related to patient service volumes, partially offset by a net increase of $8.2 million, or 1.0%, from net reimbursement-related factors. The decrease in revenue from patient service volumes was primarily related to a decline in our anesthesia and office-based women’s and children’s services, primarily as a result of

COVID-19.

The net increase in revenue related to net reimbursement-related factors was primarily due to increases in administrative fees from our hospital partners and modest improvements in managed care contracting.

Practice salaries and benefits attributable to continuing operations increased $31.2 million, or 5.0%, to $652.7 million for the three months ended March 31, 2020, as compared to $621.5 million for the same period in 2019. This increase was primarily attributable to increased costs associated with physicians and other staff to support organic-growth initiatives and growth at our existing units, as well as increases in malpractice expense due to unfavorable trends in claims experience. Of the $31.2 million increase, $20.0 million was related to salaries and $11.2 million was related to benefits and incentive compensation. We anticipate that we will continue to experience a higher rate of growth in clinician compensation expense and malpractice expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities.

Practice supplies and other operating expenses attributable to continuing operations decreased $0.5 million, or 2.0%, to $25.3 million for the three months ended March 31, 2020, as compared to $25.8 million for the same period in 2019. The decrease was primarily attributable to decreases in other practice operating expenses as compared to the prior year.

General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the

day-to-day

operations of our physician practices and services. General and administrative expenses were $105.2 million for the three months ended March 31, 2020, as compared to $101.8 million for the same period in 2019. General and administrative expenses as a percentage of net revenue was 12.4% for the three months ended March 31, 2020, as compared to 12.0% for the same period in 2019.

Transformational and restructuring related expenses attributable to continuing operations were $30.9 million for the three months ended March 31, 2020, as compared to $3.5 million for the same period in 2019. The expenses were primarily for external consulting costs for various process improvement and restructuring initiatives.

Table of Contents

Depreciation and amortization expense attributable to continuing operations was $18.7 million for the three months ended March 31, 2020, as compared to $20.0 million for the same period in 2019. The decrease of $1.3 million was primarily related to a decrease in amortization expense underlying various finite lived intangible assets due to the expiration of amortization periods.

Income from operations attributable to continuing operations decreased $65.4 million, or 83.3%, to $13.1 million for the three months ended March 31, 2020, as compared to $78.5 million for the same period in 2019. Our operating margin was 1.6% for the three months ended March 31, 2020, as compared to 9.2% for the same period in 2019. The decrease in our operating margin was primarily due to higher operating expense growth, including transformation and restructuring related expenses, and the decrease in revenue. Excluding the transformation and restructuring expenses, our income from operations attributable to continuing operations was $44.0 million, and our operating margin was 5.2%. We believe excluding the impacts from the transformational and restructuring related activity provides a more comparable view of our operating income and operating margin from continuing operations.

Total

non-operating

expenses attributable to continuing operations were $26.9 million for the three months ended March 31, 2020, as compared to $27.8 million for the same period in 2019. The decrease in

non-operating

expenses was primarily related to a decrease in interest expense, primarily due to lower average borrowings under our credit agreement (the “Credit Agreement”), partially offset by the settlement of a litigation matter.

Our effective income tax rate attributable to continuing operations was

-16.5%

and 17.7% for the three months ended March 31, 2020 and 2019, respectively. Income taxes for the first quarter of 2020 were calculated by applying the actual

year-to-date

effective rate to our

pre-tax

loss. After excluding discrete tax impacts, during the three months ended March 31, 2020 and 2019, our effective income tax rate was 20.0% and 27.0%, respectively. We believe excluding discrete tax impacts on our effective income tax rate provides a more comparable view of our effective income tax rate. The decrease in the effective tax rate during the three months ended March 31, 2020 is primarily due to the reduction in income before taxes due to the impacts from

COVID-19.

Loss from continuing operations was $16.1 million for the three months ended March 31, 2020, as compared to income from continuing operations of $41.7 million for the same period in 2019. Adjusted EBITDA from continuing operations was $63.4 million for the three months ended March 31, 2020, as compared to $104.9 million for the same period in 2019.

Diluted loss from continuing operations per common and common equivalent share was $0.20 on weighted average shares outstanding of 82.8 million for the three months ended March 31, 2020, as compared to diluted income of $0.48 on weighted average shares outstanding of 86.5 million for the same period in 2019. Adjusted EPS from continuing operations was $0.32 for the three months ended March 31, 2020, as compared to $0.65 for the same period in 2019. The decrease of 3.7 million in our weighted average shares outstanding is primarily due to the impact of shares repurchased in 2019 through open market repurchase activity and the exclusion of common stock equivalents from the weighted average shares calculation for the three months ended March 31, 2020 as the effect would have been antidilutive.

Loss from discontinued operations, net of tax, was $2.6 million for the three months ended March 31, 2020, as compared to loss of $284.5 million for the same period in 2019. Diluted loss from discontinued operations per common and common equivalent share was $0.03 for the three months ended March 31, 2020, as compared to $3.29 for the same period in 2019.

Net loss was $18.7 million for the three months ended March 31, 2020, as compared to $242.9 million for the same period in 2019. Diluted net loss per common and common equivalent share was $0.23 for the three months ended March 31, 2020, as compared to $2.81 for the same period in 2019.

Liquidity and Capital Resources

As of March 31, 2020, we had $312.2 million of cash and cash equivalents attributable to continuing operations as compared to $112.8 million at December 31, 2019. Additionally, we had working capital attributable to continuing operations of $594.5 million at March 31, 2020, an increase of $404.8 million from working capital of $189.7 million at December 31, 2019. The net increase in working capital is primarily due to net borrowings on our Credit Agreement, partially offset by a decline in operating results.

Cash Flows from Continuing Operations

Cash (used in) provided by operating, investing and financing activities from continuing operations is summarized as follows (in thousands):


	Three Months Ended March 31,
	2020			2019
Operating activities	$	(146,431	)	$	(60,408	)
Investing activities		(20,220	)		(5,271	)
Financing activities		366,039			66,664

Operating Activities from Continuing Operations

During the three months ended March 31, 2020, our net cash used in operating activities for continuing operations was $146.4 million, compared to $60.4 million for the same period in 2019. The net increase in cash used of $86.0 million was primarily due to a decrease in cash flow from lower earnings, a decrease in cash flow from changes in accounts payable and accrued expenses, primarily incentive compensation payments, and a decrease in cash flow from income taxes payable, partially offset by an increase in cash flow from accounts receivable and deferred income taxes.

Table of Contents

During the three months ended March 31, 2020, cash flow from accounts receivable for continuing operations increased by $25.9 million, as compared to a decrease of $15.9 million for the same period in 2019. The increase in cash flow from accounts receivable for the three months ended March 31, 2020 was primarily due to decreases in ending accounts receivable balances at existing units due to lower revenue.

Days sales outstanding (“DSO”) is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO for continuing operations was 51.3 days at March 31, 2020 as compared to 50.7 days at December 31, 2019. The increase in our DSO primarily related to the increases in our accounts receivable balances at existing units due to timing of cash collections.

Investing Activities from Continuing Operations

During the three months ended March 31, 2020, our net cash used in investing activities for continuing operations of $20.2 million consisted of capital expenditures of $13.7 million and net purchases of investments of $11.2 million, partially offset by proceeds from the sale of assets of $4.8 million.

Financing Activities from Continuing Operations

During the three months ended March 31, 2020, our net cash provided from financing activities for continuing operations of $366.0 million consisted of net borrowings on our Credit Agreement of $368.5 million, partially offset by the repurchase of $2.5 million of our common stock.

Liquidity

On March 25, 2020, we amended and restated our Credit Agreement to, among other things, (i) establish a deemed Consolidated EBITDA of $139.2 million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii) temporarily increase the maximum consolidated net leverage ratio required to be maintained by us from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii) require that we maintain minimum availability under the Credit Agreement of $300.0 million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0 million, plus a reserve for certain payables, and (v) temporarily restrict our ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions.

The Credit Agreement provides for a $1.2 billion unsecured revolving credit facility, subject to the limitations discussed above, and includes a $37.5 million

sub-facility

for the issuance of letters of credit. The Credit Agreement matures on March 28, 2024 and is guaranteed by substantially all of our subsidiaries and affiliated professional associations and corporations. At our option, borrowings under the Credit Agreement will bear interest at (i) the alternate base rate (defined as the higher of (a) the prime rate, (b) the Federal Funds Rate plus 1/2 of 1.00% and (c) LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated leverage ratio or (ii) the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated leverage ratio. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee ranging from 0.150% to 0.200% of the unused lending commitments, based on our consolidated leverage ratio. The Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest charge ratio, not to exceed a specified consolidated leverage ratio and to comply with laws, and restrictions on the ability to pay dividends and make certain other distributions, as specified therein. Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of the company to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement.

At March 31, 2020, we had an outstanding principal balance of $368.5 million on our Credit Agreement, of which approximately $300.0 million is included in cash on the Consolidated Balance Sheet. We also had outstanding letters of credit of $0.2 million which reduced the amount available on our Credit Agreement to $531.3 million at March 31, 2020, after giving effect to the temporary reduction of the capacity of our Credit Agreement described above through September 30, 2021.

At March 31, 2020, we had an outstanding principal balance of $750.0 million on our 5.25% senior unsecured notes due 2023 (the “2023 Notes”) and an outstanding principal balance of $1.0 billion on our 6.25% senior unsecured notes due 2027 (the “2027 Notes”). Our obligations under the 2023 Notes and the 2027 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee our Credit Agreement. Interest on the 2023 Notes accrues at the rate of 5.25% per annum, or $39.4 million, and is payable semi-annually in arrears on June 1 and December 1. Interest on the 2027 Notes accrues at the rate of 6.25% per annum, or $62.5 million, and is payable semi-annually in arrears on January 15 and July 15.

The indenture under which the 2023 Notes and the 2027 Notes are issued, among other things, limits our ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions. Although we are not required to make mandatory redemption or sinking fund payments with respect to the 2023 Notes or the 2027 Notes, upon the occurrence of a change in control of MEDNAX, we may be required to repurchase the 2023 Notes and the 2027 Notes at a purchase price equal to 101% of the aggregate principal amount of the 2023 Notes and the 2027 Notes repurchased plus accrued and unpaid interest.

Table of Contents

At March 31, 2020, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under the Credit Agreement and the 2023 Notes and the 2027 Notes. We believe we will be in compliance with these covenants throughout 2020.

We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at March 31, 2020 was $286.5 million, of which $48.1 million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $35.6 million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies.

We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund expenses related to our transformational and restructuring activities, fund our share repurchase programs and meet our contractual obligations for at least the next 12 months from the date of issuance of this Quarterly Report on Form

10-Q.

Caution Concerning Forward-Looking Statements

Certain information included or incorporated by reference in this Quarterly Report may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the 2019 Form

10-K,

including the section entitled “Risk Factors.”

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities. We intend to manage interest rate risk through the use of a combination of fixed rate and variable rate debt. We borrow under our Credit Agreement at various interest rate options based on the Alternate Base Rate or LIBOR rate depending on certain financial ratios. At March 31, 2020, the outstanding principal balance on our Credit Agreement was $368.5 million, and considering this outstanding balance, a 1% change in interest rates would result in an impact to income before income taxes of approximately $3.7 million per year.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules

13a-15(e)

and

15d-15(e)

under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2020.

Changes in Internal Controls Over Financial Reporting

No changes in our internal control over financial reporting occurred during the three months ended March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We expect that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.

In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians and other clinicians. We may also become subject to other lawsuits that could involve large claims and significant defense costs. We believe, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.

Although we currently maintain liability insurance coverage intended to cover professional liability and certain other claims, we cannot assure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable to us. With respect to professional liability risk, we self-insure a significant portion of this risk through our wholly owned captive insurance subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.

On July 10, 2018, a securities class action lawsuit was filed against our company and certain of our officers and a director in the U.S. District Court for the Southern District of Florida (Case No.

0:18-cv-61572-WPD)

that purports to state a claim for alleged violations of Sections 10(b) and 20(a) of the Exchange Act, and Rule

10b-5

thereunder, based on statements made by the defendants primarily concerning our former anesthesiology business. The complaint was seeking unspecified damages, interest, attorneys’ fees and other costs. We filed a motion to dismiss in April 2019, which was granted in October 2019; however, the plaintiff filed a second amended complaint on October 25, 2019. On November 25, 2019, we filed a motion to dismiss the second amended complaint, and on February 7, 2020 a final order granting our motion to dismiss the second amended complaint with prejudice was issued.

On March 20, 2019, a separate derivative action was filed by plaintiff Beverly Jackson on behalf of MEDNAX, Inc. against MEDNAX, Inc. and certain of its officers and directors in the Seventeenth Judicial Circuit in and for Broward County, Florida (Case Number

CACE-19-006253).

The plaintiff purported to bring suit derivatively on behalf of our company against certain of our officers and directors for breach of fiduciary duties and unjust enrichment. The derivative complaint repeated many of the allegations in the securities class action described above. We filed a motion to dismiss in December 2019, and on March 16, 2020, an order granting our motion to dismiss without prejudice was issued. On April 6, 2020, the plaintiff filed an amended complaint, and on April 30, 2020, we filed a motion to dismiss the amended complaint.

Item 1A. Risk Factors

Item 1A. Risk Factors in our most recent Annual Report on Form

10-K

includes a discussion of our risk factors. The information presented below updates, and should be read in conjunction with, the risk factors disclosed in our most recent Annual Report on Form

10-K.

Except as presented below, there have been no material changes to the risk factors disclosed in our most recent Annual Report on Form

10-K.

Our financial condition and results of operations for fiscal year 2020 and beyond may be materially adversely affected by the ongoing coronavirus

(COVID-19)

outbreak.

The outbreak of

COVID-19

has evolved into a global pandemic. The coronavirus has spread to many regions of the world, including the United States and Europe. The full extent to which the

COVID-19

outbreak will impact our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning

COVID-19

and the actions to contain it or treat its impact.

Our anesthesiology medical group, which we divested on May 6, 2020, experienced a significant decline in the number of elective surgeries at a number of the facilities where its affiliated clinicians provide anesthesia services as a result of

COVID-19.

A significant portion of this decline was due to the closure of operating suites or facilities following federal advisories to cancel

non-urgent

procedures and the prohibition of such procedures by several states. Within our radiology medical group, orders for radiological studies have declined by a meaningful amount from historically normal levels as a result of

COVID-19,

with much of this reduction focused in

non-urgent

studies. Additionally, our office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, have seen a significant elevation of appointment cancellations compared to historical normal levels as a result of

COVID-19.

To date, we have not experienced, nor do we currently anticipate, any significant impact to our neonatal intensive care unit (“NICU”) patient volumes as a result of

COVID-19,

however, there is no assurance that

COVID-19

will not adversely affect our NICU patient volumes or otherwise adversely affect our NICU and related neonatology business.

Across our medical groups, we believe that these patient volume declines primarily reflect a deferral of healthcare services utilization to a later period, rather than a permanent reduction in demand for our services. Given the general necessity of the services our affiliated clinicians provide, we anticipate that this deferral of services may create a backlog of demand in the future, in addition to the resumption of historically normal activity, however, there is no assurance that either will occur. We may also require an increased level of working capital if we

Table of Contents

experience extended billing and collection cycles as a result of displaced employees, payors, revenue cycle management contractors, or otherwise. The foregoing and other continued disruptions to our business as a result of

COVID-19

could result in a material adverse effect on our business, results of operations, financial condition, prospects and the trading prices of our securities in the near-term and beyond 2020.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended March 31, 2020, we repurchased 125,100 shares of our common stock that were withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock and deferred stock.


Period	Total Number of Shares Repurchased			Average Price Paid per Share		Total Number of Shares Purchased as part of the Repurchase Program		Approximate Dollar Value of Shares that May Yet Be Purchased Under the Repurchase Programs (a)
January 1 – January 31, 2020		40,150	(b)	$	27.17		—		(a	)
February 1 – February 29, 2020		—			—		—		(a	)
March 1 – March 31, 2020		84,950	(b)		17.09		—		(a	)

Total		125,100		$	20.33		—		(a	)

(a)

We have two active repurchase programs. Our July 2013 program allows us to repurchase shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs, which is estimated to be approximately 1.4 million shares for 2020. Our August 2018 repurchase program allows us to repurchase up to an additional $500.0 million of shares of our common stock, of which we repurchased $395.3 million as of March 31, 2020.

(b)	Represents shares withheld to satisfy minimum statutory withholding obligations of an aggregate of $2.5 million in connection with the vesting of restricted stock.

The amount and timing of any future repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.

Table of Contents

Item 6. Exhibits


Exhibit No.		Description

	10.1+	Amendment No.3, dated as of March 25, 2020, to the Credit Agreement, dated as of October 30, 2017, among MEDNAX, Inc., certain of its domestic subsidiaries from time to time party thereto as Guarantors, the Lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent.

	31.1+	Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

	31.2+	Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

	32.1*	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

	101.1+	Interactive Data File

	101.INS+	XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

	101.SCH+	XBRL Schema Document.

	101.CAL+	XBRL Calculation Linkbase Document.

	101.DEF+	XBRL Definition Linkbase Document.

	101.LAB+	XBRL Label Linkbase Document.

	101.PRE+	XBRL Presentation Linkbase Document.

	104+	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

+	Filed herewith.

*	Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	MEDNAX, INC.

Date: May 7, 2020	By:	/s/ *Roger J. Medel, M.D.*
		Roger J. Medel, M.D.
		Chief Executive Officer
		(Principal Executive Officer)

Date: May 7, 2020	By:	/s/ *Stephen D. Farber*
		Stephen D. Farber
		Chief Financial Officer
		(Principal Financial Officer)

Date: May 7, 2020	By:	/s/ *John C. Pepia*
		John C. Pepia
		Chief Accounting Officer
		(Principal Accounting Officer)

This ‘10-Q’ Filing	Date	Other Filings

	3/28/24
	12/31/22
	12/31/21
	9/30/21
	1/1/21
	12/31/20
	6/30/20	10-Q
Filed on:	5/7/20	8-K
	5/6/20	8-K
	5/1/20
	4/30/20
	4/6/20
For Period end:	3/31/20
	3/27/20
	3/25/20	8-K
	3/16/20
	2/29/20
	2/20/20	10-K, 8-K
	2/7/20
	1/31/20
	1/1/20
	12/31/19	10-K, 10-K/A
	11/25/19
	10/31/19
	10/25/19
	10/10/19	8-K
	3/31/19	10-Q
	3/20/19
	1/1/19
	7/10/18
		List all Filings

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/20/24  Pediatrix Medical Group, Inc.     10-K       12/31/23   99:12M                                    Donnelley … Solutions/FA
 2/17/23  Pediatrix Medical Group, Inc.     10-K       12/31/22   97:14M                                    Donnelley … Solutions/FA
 2/17/22  Pediatrix Medical Group, Inc.     10-K       12/31/21   96:13M                                    Donnelley … Solutions/FA
 2/18/21  Pediatrix Medical Group, Inc.     10-K       12/31/20   96:10M                                    Donnelley … Solutions/FA

↑Top

Filing Submission 0001193125-20-136311 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Accelerated filer

i Large accelerated filer

Non-accelerated
filer

Smaller reporting company

Emerging growth company